A clinical trial is being initiated at Northwestern University in Chicago, Illinois. The aim of the study is to test the safety and efficacy of once weekly dosing of oral prednisone, a glucocorticoid steroid.

Both ambulatory and nonambulatory patients with Limb Girdle Muscular Dystrophy (LGMD) types 2A, 2B, 2C, 2E, 2F, 2I, 2L, and Becker Muscular Dystrophy are sought to participate. Glucocorticoid steroids are a standard therapy for Duchenne Muscular Dystrophy (DMD). Studies in patients with DMD show that weekly dosing is associated with reduced side effects compared to daily dosing. Recent investigations of weekly dosing of glucocorticoid steroids in mouse models of LGMD 2B and 2C showed improved muscle strength, suggesting that this may be a beneficial therapy for LGMD patients.